RBM3 in bladder cancer
US9701741B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 11, 2012 |
| Grant date | Jul 11, 2017 |
| Priority date | — |
| Expiry date | May 11, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates, in one of its aspects, to a method for determining whether a mammalian subject having a bladder cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: a) evaluating an amount of RBM3 in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; b) comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to the second group.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.